Charles Peloquin

Charles Peloquin Pharm.D.

Professor & Director, Infectious Disease Pharmacokinetics Laboratory

Department: Pharmacotherapy & Translational Research
Business Phone: (352) 273-6266
Business Email: peloquin@cop.ufl.edu

About Charles Peloquin

Prior to coming to the University of Florida, Dr. Peloquin completed a hospital pharmacy residency at Duke University Medical Center, where he also served on the clinical staff. He also completed a fellowship in Infectious Diseases and Pharmacokinetics at the Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, N.Y. For 20 years, Dr. Peloquin was the Director of the Infectious Disease Pharmacokinetics Laboratory (IDPL) at National Jewish Medical and Research Center, Denver, CO. He now serves as Professor of Pharmacy and Medicine at UF, where the IDPL is now located. Dr. Peloquin and his lab are part of the UF Emerging Pathogens Institute. He also is a consultant to the FDA and CDC.

Honors & Awards

Member
2004-Current · International Society of Antimicrobial Pharmacology
Member
1991-Current · Society of Infectious Disease Pharmacists
Member
1990-Current · American Society of Microbiology
Member
1986-Current · American College of Clinical Pharmacy

Research Profile

Dr. Peloquin’s laboratory serves as a national reference center for the determination of serum concentrations for the antimycobacterial, antifungal, and anti-HIV drugs, as well as linezolid. His research efforts focus on therapeutic drug monitoring and clinical trials for patients with advanced mycobacterial diseases.

Publications

2015 Clinical Pharmacology & Therapeutics
2012 Expert Opinion on Pharmacotherapy
2011 American Journal of Respiratory and Critical Care Medicine

Grants

February 2019ACTIVE
Diagnostics and Pharmacotherapy for Severe Forms of TB
UNIV OF VIRGINIA · Principal Investigator
September 2018ACTIVE
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
NATL INST OF HLTH NICHD ·
July 2018ACTIVE
An Exploratory Study of Anti-Tuberculosis Drug Penetration into Cerebrospinal Fluid
EMORY UNIV · Principal Investigator
February 2018 – January 2019
Diagnostics and Pharmacotherapy for Severe Forms of TB
UNIV OF VIRGINIA · Principal Investigator
October 2017 – December 2018
Screening and Treatment of Children and Adults Exposed at Home to Drug-Resistant Tuberculosis
HARVARD MEDICAL SCHOOL · Principal Investigator
August 2017ACTIVE
Predictors of Resistance Emergence Evaluation in MDR-TB Patients on Treatment (PREEMPT)
BOSTON UNIV · Principal Investigator
August 2016ACTIVE
Optimizing combination therapy for accelerate clinical cure of tuberculosis
NATL INST OF HLTH NIAID ·
July 2016 – May 2017
Pharmacokinetics of second-line anti-tuberculosis drugs among patients with multidrug-resistant tuberculosis
INTL SCIENCE AND TECHNOLOGY CENTER · Principal Investigator
June 2016 – August 2018
Pharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in Children
NATL INST OF HLTH NICHD ·
February 2016 – January 2018
MD-INMD Diagnostics and Pharmacotherapy for Service Year 2
UNIV OF VIRGINIA · Principal Investigator
February 2016 – January 2018
A Clinical Pharmacology Study of a Novel Drug Regimen for Pre XDR and XDR Tuberculosis
EMORY UNIV · Principal Investigator
February 2014 – February 2017
Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated with Efavirenz Therapy
BRIGHAM AND WOMENS HOSPITAL · Principal Investigator
August 2013 – July 2018
Phase 2 Pharmacodynamic Study of High-dose Levofloxacin in MDR-TB Treatment
BOSTON UNIV · Principal Investigator
June 2009ACTIVE
Moxifloxain PK in Bile.
MULTIPLE SPONSORS · Principal Investigator

Education

1986
Pharm.D.
Philadelphia College of Pharmacy and Science
1981
B.S.
University of Connecticut